Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 82Myelodysplastic Syndromes 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 69Leukemia, Lymphocytic, Chronic, B-Cell 69Lymphoma, Non-Hodgkin 63Hodgkin Disease 62Leukemia 56Multiple Myeloma 52Lymphoma 46Lymphoma, Follicular 44Lymphoma, Mantle-Cell 41Leukemia, Myelogenous, Chronic, BCR-ABL Positive 41Lymphoma, Large B-Cell, Diffuse 40Lymphoma, B-Cell, Marginal Zone 39Myeloproliferative Disorders 36Burkitt Lymphoma 35Congenital Abnormalities 29Lymphoma, Large-Cell, Immunoblastic 27Leukemia, Myelomonocytic, Chronic 27Hematologic Neoplasms 27Leukemia, Myeloid, Chronic-Phase 26Waldenstrom Macroglobulinemia 22Neoplasms, Plasma Cell 22Leukemia, Myeloid, Accelerated Phase 22Anemia, Refractory, with Excess of Blasts 22Graft vs Host Disease 21Primary Myelofibrosis 20Recurrence 19Leukemia, Prolymphocytic 19Dendritic Cell Sarcoma, Interdigitating 18

Interventions

Cyclophosphamide 3thymoglobulin 2fludarabine 2Rituximab 2Melphalan 2Busulfan 2fludarabine phosphate 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Mycophenolic Acid 1Levetiracetam 1Dexamethasone 1Bortezomib 1Antilymphocyte Serum 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × beta-Thalassemia × Mycophenolic Acid × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡